Succeed Together

At Tetra Bio-Pharma, strategic partnerships are an integral part of our business model and success. We join forces within the biopharmaceuticals, natural health and veterinary products industries and collaborate with leaders in academia, patient organizations and other research-based groups — all with a shared interest in developing cannabinoid-derived products based on the foundation of rigorous scientific evidence that meets the standards of regulators, medical bodies and insurers. Our strategic partnerships allow us to expand and strengthen our diverse pharmaceutical pipeline and develop innovative solutions to improve healthcare centered around patient outcomes ranging from prevention, treatment and wellness.

Strategic Partnerships

Altasciences is an international contract research organization specializing in clinical pharmacology and bioanalysis of preclinical and clinical programs. Their research supports the commercialization of generic drugs (copies of drugs), which are less expensive than brand name drugs, and participates in the development of new drugs.

The Alternavida Group began operations in 1997 with the commitment of addressing the needs of the Mexican Health Sector. Alternavida’s initial focus was in the commercialization and access to therapeutic technologies of high specialty products / therapies in the areas of oncology, immunology, blood derived products, and others.  Alternavida’s group of companies are now involved in the manufacturing of oncology and other branded generic products as well as partnering with innovative companies to market their therapies in Mexico. Throughout the years we have learned how to build long lasting partnerships that allows us to better serve our customers and patients. Alternavida Group Mission: To deliver value by creating health related alliances.
Altus Formulation is a Quebec based drug formulation and development company using its proprietary and patent protected drug delivery technologies to generate novel, differentiated and cost-effective new products for its partners and their patients. With a focus on Safer to Use™ formulations, Altus’ technologies include Intellitab™ abuse deterrent technology, Flexitab™ breakable extended release tablets and SmartCelle™ technologies for intravenous or oral delivery of low solubility large and small molecules.
Azevedos Group is a 200 year old Portuguese pharmaceutical brand, whose wide scope of activity ranges from development to manufacturing, and distribution, in more than 80 regulated countries worldwide. Azevedos owns more than 300 Marketing Authoizations for the most relevant therapeutic areas covering all technology forms manufactured at its state of the art plant holding the most recognized certifications.

Cellvera is a biopharmaceutical company focused on discovering, developing, and commercializing oral therapies and monitoring tools to address the unmet medical needs of patients with life-threatening viral diseases.  Tetra and Cellvera will jointly develop an oral drug candidate to combat viral diseases by  leveraging expertise and resources form both companies.  www.cellvera.com

DanCann Pharma A/S (SS: DANCAN) was founded in 2018 and is a Danish biopharmaceutical company powered by cannabinoids. DanCann Pharma is a vertically integrated, licensed production and distribution company based in Denmark. The company focuses on discovering, developing, manufacturing, and commercializing new therapeutic cannabinoids in a wide range of disease areas.

The George Mason University National Center for Biodefense and Infectious Diseases (NCBID) is a leading institute in the USA conducting pioneering research on infectious diseases including diagnostic, therapeutics, and vaccine development. Tetra, the George Mason University (NCBID), and Targeted Pharmaceuticals Inc. have established a research collaboration to evaluate ARDS-003 in animals infected with SARS-CoV-2.

Since 2001, Innomar Strategies has provided an unparalleled balance between patient care and market access, and continue to deliver innovative solutions to specialty manufacturers to improve product access, increase supply chain efficiency, and ultimately enhance patient care.

Tetra Bio-Pharma and IntelGenx Corp. have a definitive agreement for the development and commercialization of a drug product containing the cannabinoid Dronabinol XL – PPP002 for the management of anorexia and chemotherapy-induced nausea and vomiting.

Kamada Ltd. is focused on plasma-derived protein therapeutics for orphan indications, and has a commercial product portfolio and a late-stage product pipeline. The Company uses its proprietary platform technology and know-how for the extraction and purification of proteins from human plasma to produce Alpha-1 Antitrypsin (AAT) in a highly-purified, liquid form, as well as other plasma-derived Immune globulins. The Company’s flagship product is GLASSIA®, the first liquid, ready-to-use, intravenous plasma-derived AAT product approved by the U.S. Food and Drug Administration. Kamada markets GLASSIA® in the U.S. through a strategic partnership with Takeda Pharmaceuticals Company Limited and in other counties through local distributors. Kamada also leverages its expertise and presence in the plasma-derived protein therapeutics market by distributing more than 20 complementary products in Israel that are manufactured by third parties.

McGill University is collaborating with Tetra Bio-Pharma on an NSERC (National Sciences and Engineering Research Council) funded research study to examine the effects of cannabinoids on health, inflammation, and the microbiome of the gut.

NSERC – The National Sciences and Engineering Research Council of Canada connects industry players with world-firsts in knowledge and the people behind them, fueling R&D and leading to firsts in the marketplace. They have granted Tetra Bio-Pharma research funding related to the effects of cannabinoids on health, inflammation, and the microbiome of the gut.

PREPAIRE is an Ai-powered drug discovery platform using a proprietary algorithm based on Convolutional Deep Neural Networks (CNN) and Generative Adversarial Networks (GANs) to build reactive chemical and biological fitting models enabling the identification ligands to protein targets, protein-protein interactions, generating molecular structures with specified properties combining both functionality and drug ability, as well as preparing synthetic data for specific drug discovery and personalized treatment. PREPAIRE offers a partnership eco-system. The outcome of PREPAIRE accelerates all steps of drug discovery and development, including target discovery, lead optimization, toxicity assessment, and trial design. www.prepaire.com

The Ontario Lung Association is a not-for-profit organization dedicated to helping all Canadians breathe. Their community of donors, patients, researchers, volunteers and professional staff work to promote healthy breathing, support those living with lung disease and find future solutions.

Targeted Pharmaceuticals Inc. is a cannabinoid-based biopharmaceutical company focused on drug discovery & personalized medicine derived from plant-based therapeutics and combination therapies. Tetra, Targeted Pharmaceuticals Inc., and the George Mason University (NCBID) have established a research collaboration to evaluate ARDS-003 in animals infected with SARS-CoV-2.

Tetra Bio-Pharma and The New Brunswick Health Research Foundation are investing a combined $1 million, $500,000 each over five years to establish a Health Research Chair in Cannabis at the University of New Brunswick (UNB). The Chair will focus on the study of biochemistry, medicinal use and pharmacology of cannabis. This research will expand UNB’s commitment to research and innovation in the field of biomedical, health and life sciences.